Name: Cytokinetics Inc. (NASDAQ:CYTK) | Income Statement
Creator: Stock Analysis on Net

Income Statement

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Download chart

Cytokinetics Inc., consolidated income statement

US$ in thousands

12 months ended:	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Research and development revenues	6,588)	10,572)	16,527)	26,868)	26,368)
License revenues	—)	54,856)	36,501)	—)	5,133)
Milestone revenues	1,000)	5,000)	2,800)	—)	—)
Realization of revenue participation right purchase agreement	87,000)	—)	—)	—)	—)
Revenues	94,588)	70,428)	55,828)	26,868)	31,501)
Research and development	(240,813)	(159,938)	(96,951)	(86,125)	(89,135)
General and administrative	(177,977)	(96,803)	(52,820)	(39,610)	(31,282)
Operating expenses	(418,790)	(256,741)	(149,771)	(125,735)	(120,417)
Operating loss	(324,202)	(186,313)	(93,943)	(98,867)	(88,916)
Interest expense	(19,414)	(16,440)	(15,963)	(6,623)	(3,797)
Loss on settlement of debt	(24,939)	—)	—)	—)	—)
Non-cash interest expense on liabilities related to revenue participation right purchase agreements	(31,742)	(12,892)	(22,713)	(20,737)	(17,767)
Interest and other income, net	11,342)	331)	5,329)	4,535)	4,191)
Loss, before income tax provision	(388,955)	(215,314)	(127,290)	(121,692)	(106,289)
Income tax provision	—)	—)	—)	—)	—)
Net loss	(388,955)	(215,314)	(127,290)	(121,692)	(106,289)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

The financial trajectory from 2018 to 2022 is characterized by a significant increase in total revenues alongside a disproportionate escalation in operating expenses, leading to widening net losses.

Revenue Composition and Trends: Total revenues grew from US$ 31.5 million in 2018 to US$ 94.6 million in 2022. This growth was not uniform across all streams. Research and development revenues exhibited a consistent downward trend, falling from US$ 26.4 million in 2018 to US$ 6.6 million in 2022. Conversely, license revenues emerged as a significant contributor, peaking at US$ 54.9 million in 2021. The revenue spike in 2022 was primarily driven by a one-time realization of a revenue participation right purchase agreement totaling US$ 87 million.
Operating Expense Escalation: Operating expenses increased substantially over the five-year period, rising from US$ 120.4 million in 2018 to US$ 418.8 million in 2022. Research and development spending saw a marked increase, accelerating from US$ 89.1 million in 2018 to US$ 240.8 million in 2022. General and administrative expenses followed a similar upward trajectory, growing from US$ 31.3 million in 2018 to US$ 178.0 million in 2022, indicating a significant increase in the company's operational scale or overhead.
Profitability and Loss Trajectory: The operating loss expanded significantly, moving from US$ 88.9 million in 2018 to US$ 324.2 million in 2022. The net loss followed this pattern, widening from US$ 106.3 million in 2018 to US$ 389.0 million in 2022. The rate of loss acceleration increased sharply after 2020, coinciding with the steep rise in both research and administrative expenditures.
Non-Operating Financial Impacts: Interest expenses grew steadily from US$ 3.8 million in 2018 to US$ 19.4 million in 2022. Additionally, non-cash interest expenses related to revenue participation right purchase agreements fluctuated, reaching a peak of US$ 31.7 million in 2022. The net loss in 2022 was further impacted by a one-time loss on the settlement of debt amounting to US$ 24.9 million.

AI Ask an analyst for more

My previous chats

Add tokens

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?